Archie Bleyer

TL;DR: The Global Burden of Disease (GBD) study as discussed by the authors has been used to describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning, including cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs).

TL;DR: Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer, suggesting that screening is having, at best, only a small effect on the rate of death from breast cancer.

TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 as mentioned in this paper was the most recent iteration of the GBD, which used all available data to produce estimates of mortality rates between 1950 and 2017 for 23 age groups.

TL;DR: Chemotherapy, endocrine, and local therapies have the potential to significantly impact both the physiologic health-including future fertility, premature menopause, and bone health-and the psychological health of young women as they face a diagnosis of breast cancer.